Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q412616> ?p ?o }
Showing triples 1 to 83 of
83
with 100 triples per page.
- Q412616 subject Q22948482.
- Q412616 subject Q5016550.
- Q412616 subject Q6809004.
- Q412616 subject Q6814466.
- Q412616 subject Q8654892.
- Q412616 abstract "Trastuzumab (INN; trade names Herclon, Herceptin) is a monoclonal antibody that interferes with the HER2/neu receptor. Its main use is to treat certain breast cancers.The HER receptors are proteins that are embedded in the cell membrane and communicate molecular signals from outside the cell (molecules called EGFs) to inside the cell, and turn genes on and off. The HER protein, Human Epidermal Growth Factor Receptor, binds to Human Epidermal Growth Factor, and stimulates cell proliferation. In some cancers, notably certain types of breast cancer, HER2 is over-expressed, and causes cancer cells to reproduce uncontrollably.A 2014 Cochrane Review examined the safety and efficacy of trastuzumab-containing combination therapies (with chemotherapy, hormone blockers, or lapatinib) for the treatment of metastatic breast cancer. The overall hazard ratios for overall survival and progression free survival were 0.82 and 0.61 respectively. It was difficult to accurately ascertain the true impact of trastuzumab on survival, as in three of the seven trials, over half of the patients in the control arm were allowed to cross over and receive trastuzumab after their cancer began to progress. Thus this analysis likely underestimates the true survival benefit associated with trastuzumab treatment in this population. In these trials, trastuzumab also increased the risk of heart problems, including heart failure (RR 3.49) and left ventricular ejection fraction decline (RR 2.65).In early stage (curable) HER2-positive breast cancer, trastuzumab-containing regimens improved overall survival (HR 0.66) and disease-free survival (HR 0.60) relative to comparator arms involving treatment with placebo or chemotherapy. Increased risk of heart failure (RR 5.11) and decline in left ventricular ejection fraction (RR 1.83) were seen in these trials as well. Two trials involving shorter term treatment with trastuzumab did not differ in efficacy from longer trials, but produced less cardiac toxicity.It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system. The wholesale price is between 1,800.00 and 1,955.00 USD per vial.".
- Q412616 atcPrefix "L01".
- Q412616 atcSuffix "XC03".
- Q412616 casNumber "180288-69-1".
- Q412616 drugbank "DB00072".
- Q412616 fdaUniiCode "P188ANX8CK".
- Q412616 wikiPageExternalLink herceptinr.
- Q412616 wikiPageExternalLink trastuzumab.
- Q412616 wikiPageExternalLink 0,,1742168,00.html.
- Q412616 wikiPageExternalLink index.jsp.
- Q412616 wikiPageExternalLink ?tool=pubmed.
- Q412616 wikiPageWikiLink Q11000047.
- Q412616 wikiPageWikiLink Q1189226.
- Q412616 wikiPageWikiLink Q128581.
- Q412616 wikiPageWikiLink Q133226.
- Q412616 wikiPageWikiLink Q1336182.
- Q412616 wikiPageWikiLink Q14864695.
- Q412616 wikiPageWikiLink Q14877486.
- Q412616 wikiPageWikiLink Q17067368.
- Q412616 wikiPageWikiLink Q174710.
- Q412616 wikiPageWikiLink Q176996.
- Q412616 wikiPageWikiLink Q181754.
- Q412616 wikiPageWikiLink Q186889.
- Q412616 wikiPageWikiLink Q188941.
- Q412616 wikiPageWikiLink Q1926141.
- Q412616 wikiPageWikiLink Q2038124.
- Q412616 wikiPageWikiLink Q2072214.
- Q412616 wikiPageWikiLink Q208467.
- Q412616 wikiPageWikiLink Q20969983.
- Q412616 wikiPageWikiLink Q216933.
- Q412616 wikiPageWikiLink Q22948482.
- Q412616 wikiPageWikiLink Q2296168.
- Q412616 wikiPageWikiLink Q2304142.
- Q412616 wikiPageWikiLink Q2624248.
- Q412616 wikiPageWikiLink Q3120948.
- Q412616 wikiPageWikiLink Q37155.
- Q412616 wikiPageWikiLink Q3997863.
- Q412616 wikiPageWikiLink Q40878.
- Q412616 wikiPageWikiLink Q417589.
- Q412616 wikiPageWikiLink Q420323.
- Q412616 wikiPageWikiLink Q422248.
- Q412616 wikiPageWikiLink Q423650.
- Q412616 wikiPageWikiLink Q423725.
- Q412616 wikiPageWikiLink Q46292.
- Q412616 wikiPageWikiLink Q4826483.
- Q412616 wikiPageWikiLink Q5016550.
- Q412616 wikiPageWikiLink Q539568.
- Q412616 wikiPageWikiLink Q546395.
- Q412616 wikiPageWikiLink Q5628425.
- Q412616 wikiPageWikiLink Q576711.
- Q412616 wikiPageWikiLink Q6275910.
- Q412616 wikiPageWikiLink Q6589727.
- Q412616 wikiPageWikiLink Q6809004.
- Q412616 wikiPageWikiLink Q6814466.
- Q412616 wikiPageWikiLink Q7180724.
- Q412616 wikiPageWikiLink Q7281300.
- Q412616 wikiPageWikiLink Q7920223.
- Q412616 wikiPageWikiLink Q7935126.
- Q412616 wikiPageWikiLink Q824258.
- Q412616 wikiPageWikiLink Q847583.
- Q412616 wikiPageWikiLink Q864715.
- Q412616 wikiPageWikiLink Q8654892.
- Q412616 wikiPageWikiLink Q899140.
- Q412616 wikiPageWikiLink Q899285.
- Q412616 wikiPageWikiLink Q899651.
- Q412616 wikiPageWikiLink Q91442.
- Q412616 atcPrefix "L01".
- Q412616 atcSuffix "XC03".
- Q412616 casNumber "180288".
- Q412616 drugbank "DB00072".
- Q412616 unii "P188ANX8CK".
- Q412616 type ChemicalSubstance.
- Q412616 type Drug.
- Q412616 type ChemicalObject.
- Q412616 type Thing.
- Q412616 type Q8386.
- Q412616 comment "Trastuzumab (INN; trade names Herclon, Herceptin) is a monoclonal antibody that interferes with the HER2/neu receptor. Its main use is to treat certain breast cancers.The HER receptors are proteins that are embedded in the cell membrane and communicate molecular signals from outside the cell (molecules called EGFs) to inside the cell, and turn genes on and off. The HER protein, Human Epidermal Growth Factor Receptor, binds to Human Epidermal Growth Factor, and stimulates cell proliferation.".
- Q412616 label "Trastuzumab".